Psychiatric diagnosis

Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Thursday, July 29, 2021

The Company is scheduled to present at the conference at9:30 am Eastern Time the same day via webcast.

Key Points: 
  • The Company is scheduled to present at the conference at9:30 am Eastern Time the same day via webcast.
  • A live audio webcast of the conference presentation will be available online at the investor relations page of the Companys website at ir.neuronetics.com .
  • Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.
  • NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japans national health insurance.

AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC

Retrieved on: 
Thursday, July 29, 2021

AB Science SA (Euronext - FR0010557264 - AB) today announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimers disease have been presented at the annual Alzheimers Association International Conference (AAIC) (July 26-30, 2021).

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimers disease have been presented at the annual Alzheimers Association International Conference (AAIC) (July 26-30, 2021).
  • The AAIC is the largest and most influential international meeting dedicated to the latest Alzheimers and dementia research.
  • This year the Alzheimers Association International Conference (AAIC) is taking place both in person (Denver, USA) and online (hybrid model of delivery).
  • Study AB09004 was the first successful phase 3 randomized trial in mild-to-moderate Alzheimers disease of a drug targeting innate immune cells of the neuroimmune system.

Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies

Retrieved on: 
Friday, July 30, 2021

Aggregation of tau is highly associated with the progression of neurodegenerative disorders, including Alzheimers disease, frontotemporal dementia and progressive supranuclear palsy, said James Moe, Ph.D., MBA, President and CEO of Oligomerix.

Key Points: 
  • Aggregation of tau is highly associated with the progression of neurodegenerative disorders, including Alzheimers disease, frontotemporal dementia and progressive supranuclear palsy, said James Moe, Ph.D., MBA, President and CEO of Oligomerix.
  • The data from our preclinical studies continue to support our differentiated approach targeting tau self-association, an upstream mechanism at the beginning of the tau aggregation cascade, for reducing tau pathology.
  • These preclinical studies support the advancement of OLX-07010 into clinical studies for Alzheimers disease and rare tauopathies.
  • Oligomerix plans to complete preclinical testing of OLX-07010 by year end and begin Phase 1 clinical trials in 2Q22.

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease

Retrieved on: 
Friday, July 30, 2021

The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.

Key Points: 
  • The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.
  • "Our Phase 3 study provides us the opportunity to gain valuable insights about the potential effectiveness of Nilotinib BE in treating early Alzheimer's."
  • KeifeRx will launch a national, multicenter, placebo-controlled, double-blind study of Nilotinib BE in early Alzheimer's disease.
  • The primary objectives of the study are to investigate the safety and efficacy of Nilotinib BE on the progression of dementia in early Alzheimer's disease.

Highlights From The Alzheimer's Association International Conference 2021

Retrieved on: 
Thursday, July 29, 2021

DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.
  • Other new data reported at AAIC 2021 included:
    Improving air quality may reduce dementia risk.
  • "As the leading voluntary health organization in Alzheimer's research, care and support, the Alzheimer's Association believes we're living in a new era of advancement.
  • The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

Highlights From The Alzheimer's Association International Conference 2021

Retrieved on: 
Thursday, July 29, 2021

DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.
  • Other new data reported at AAIC 2021 included:
    Improving air quality may reduce dementia risk.
  • The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.
  • The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

A New Resource for Families in the Greater Wausau Area: A Therapy Center Designed for Children on the Autism Spectrum

Retrieved on: 
Thursday, July 29, 2021

The center is a colorful, child-friendly place created especially for young people with autism.

Key Points: 
  • The center is a colorful, child-friendly place created especially for young people with autism.
  • Caravel previously offered in-home therapy in the Greater Wausau area.
  • Since 2009, Caravel Autism Health has been devoted to helping families navigate the challenges of childhood autism.
  • Our team of clinical experts specializes in the evaluation, diagnosis, and treatment of children on the autism spectrum.

Autism Learning Partners Announces Expansion to Eugene, OR in Response to the Substantial Waiting Lists for In-Home ABA Services

Retrieved on: 
Thursday, July 29, 2021

ALP initiated this extension in response to the need for quality in-home services as well as the current substantial waiting lists in the community.

Key Points: 
  • ALP initiated this extension in response to the need for quality in-home services as well as the current substantial waiting lists in the community.
  • ALP is committed to continuing collaborative efforts with related service providers, EI/ECSE programs, and school districts in the Eugene area.
  • Services include: Applied Behavioral Analysis and additionally offer speech, occupational, physical therapies, and diagnostic services in select regions.
  • To learn more about Autism Learning Partners and its services, please visit http://www.AutismLearningPartners.com .